SEMINAR FRIDAY 29.11.2013

PLACE: “Laboratoriebygget” Meetingroom 9.1, 9th floor
TIME : 12:00-13:00

SPEAKER/TITLE:
1. Professor Bjørn Tore Gjertsen, University of Bergen, Department of Clinical Science
   Translational targeted therapy in malignancies

2. Professor James Lorens, University of Bergen, The Department of Biomedicine
   Axl-inhibitors, a way forward in pancreatic cancer?

3. Researcher Spiros Kotopoulis, University of Bergen
   Sonoporation and its effect in pancreatic cancer

ABSTRACTS

Gjertsen
The most aggressive cancers and metastatic disease need a more precise therapeutic strategy to improve survival and avoid unnecessary toxicities. Current development in targeted therapy in cancer follow predominantly along three main mechanisms of action: i) small molecules against enzymes or adaptor proteins that is predominantly expressed or functional pivotal in the malignant cells, ii) designed antibodies or decoy receptors that block receptor function in cancer cells, and iii) physical directed therapy against the location of the cancer cells. An intensive research effort is addressing tumor-host interaction, in particularly anti-angiogenesis and immunological anti-cancer effects. A slow development of biomarkers seems to limit the selection of patients for these novel targeted therapies. Development of biomarkers from animal models to patients will be discussed, and some advantages of the Haukeland Campus and the MedViz visualization cluster will be illustrated.

Lorens
TBA

Kotopoulis
Sonoporation is a newly blooming technique used to enhance local drug and gene delivery. Dr. Spiros Kotopoulis will talk about the background of this technique, and walk through how this technique went from a physics lab to the clinic trials within 3 years. He will also discuss some preliminary results from the clinical trials showing the benefits of sonoporation.